Response outcomes in patients with Ras/MAPK gene mutations at baseline
| Response parameter, n (%) . | Gilteritinib (n = 18) . | Salvage chemotherapy (n = 7) . | Total (N = 25) . | |
|---|---|---|---|---|
| FLT3-ITD (n = 13) . | FLT3-TKD (n = 5) . | FLT3-ITD (n = 7) . | ||
| CR | 1 (7.7) | 1 (20.0) | 1 (14.3) | 3 (12.0) |
| CRp | 2 (15.4) | 0 | 0 | 2 (8.0) |
| CRi | 1 (7.7) | 1 (20.0) | 0 | 2 (8.0) |
| CRh | 2 (15.4) | 0 | 0 | 2 (8.0) |
| PR | 0 | 0 | 0 | 0 |
| NR | 7 (53.8) | 2 (40.0) | 4 (57.1) | 13 (52.0) |
| NE | 2 (15.4) | 1 (20.0) | 2 (28.6) | 5 (20.0) |
| CR/CRh | 3 (23.1) | 1 (20.0) | 1 (14.3) | 5 (20.0) |
| CRc* | 4 (30.8) | 2 (40.0) | 1 (14.3) | 7 (28.0) |
| Response parameter, n (%) . | Gilteritinib (n = 18) . | Salvage chemotherapy (n = 7) . | Total (N = 25) . | |
|---|---|---|---|---|
| FLT3-ITD (n = 13) . | FLT3-TKD (n = 5) . | FLT3-ITD (n = 7) . | ||
| CR | 1 (7.7) | 1 (20.0) | 1 (14.3) | 3 (12.0) |
| CRp | 2 (15.4) | 0 | 0 | 2 (8.0) |
| CRi | 1 (7.7) | 1 (20.0) | 0 | 2 (8.0) |
| CRh | 2 (15.4) | 0 | 0 | 2 (8.0) |
| PR | 0 | 0 | 0 | 0 |
| NR | 7 (53.8) | 2 (40.0) | 4 (57.1) | 13 (52.0) |
| NE | 2 (15.4) | 1 (20.0) | 2 (28.6) | 5 (20.0) |
| CR/CRh | 3 (23.1) | 1 (20.0) | 1 (14.3) | 5 (20.0) |
| CRc* | 4 (30.8) | 2 (40.0) | 1 (14.3) | 7 (28.0) |
Bold font indicates aggregate responses.
CRi, complete remission with incomplete hematologic recovery; CRp, complete remission with incomplete platelet recovery; NE, not evaluable; NR, no response; ORR, overall response rate; PR, partial remission.
Defined as the sum of patients who achieved CR, CRi, and CRp.